Dr Li Yi-Heng

Cardiologist, National Cheng Kung University Hospital, Taiwan

<img src="https://cardiothinklab.com/wp-content/uploads/2021/07/Dr-James-Januzzi-Cardio-ThinkLab-296x300.jpg" width="300" height="300">

Dr James L Januzzi

Cardiologist, Massachusetts General Hospital. Prof of Medicine, Harvard Medical School

Home > Education & CME > Webinar > NT-proBNP in Hospital & Ambulatory Settings: Evidence to Clinical Practice

NT-proBNP in Hospital & Ambulatory Settings: Evidence to Clinical Practice

17 September 2020

KEY TAKEAWAYS

Biomarkers play a useful role in the comprehensive management of patients with Heart Failure
NT-proBNP is used in Emergency Departments, ward and outpatient setting
In the era of ARNi, NT-proBNP is more useful than BNP for monitoring treatment

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy.

28 March 2023

Prof Alexandre Mebazaa

CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021

<img src="https://cardiothinklab.com/wp-content/uploads/2021/07/Dr-James-Januzzi-Cardio-ThinkLab-296x300.jpg" width="300" height="300">

Dr James L Januzzi